Multiple sclerosis outcomes after cancer immunotherapy

ConclusionsReported MS relapses after ICI are rare, but the adverse events described include rapid neurologic progression and death. Larger and prospective studies are warranted to assess disability and long-term outcomes and outweigh the risks of starting immunotherapy in patients with MS.

http://link.springer.com/10.1007/s12094-019-02060-8

Source: Clinical and Translational Oncology - February 20, 2019 Category: Cancer & Oncology Source Type: research